Oncology

Novartis says it can deliver doses to treatment sites with 5 days of order.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

CRC treatment delays were linked to higher metastatic risk, but meaningful thresholds varied by treatment pathway, supporting tailored benchmarks.

Patients with a history of nonmelanoma skin cancer had a 548% greater likelihood to develop another skin cancer vs those with no cancer history.

Hepatitis B and C prevention programs improve detection, treatment, and liver outcomes, but screening, care access, and implementation gaps remain.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Financial toxicity in pediatric cancer extends beyond medical bills, affecting treatment adherence, caregivers, and survivors long-term, Cherie Daly, MD, said.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Rising oncology costs and fragmented data compromise care. Payers must adopt a blueprint integrating clinical intelligence, next-generation utilization management, and partnerships to achieve measurable value.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.